Recent Analysts’ Ratings Updates for Ekso Bionics (EKSO)

Ekso Bionics (NASDAQ: EKSO) recently received a number of ratings updates from brokerages and research firms:

• 11/11/2024 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/3/2024 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/29/2024 – Ekso Bionics had its price target lowered by analysts at Lake Street Capital from $2.50 to $2.00. They now have a “buy” rating on the stock.
• 10/29/2024 – Ekso Bionics had its price target lowered by analysts at HC Wainwright from $10.00 to $9.00. They now have a “buy” rating on the stock.
• 10/26/2024 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/18/2024 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/10/2024 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/2/2024 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 9/24/2024 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 9/16/2024 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

Ekso Bionics Trading Down 1.3 %

NASDAQ EKSO opened at $0.76 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The company has a market capitalization of $16.70 million, a price-to-earnings ratio of -1.17 and a beta of 1.47. The company’s 50-day simple moving average is $1.05 and its two-hundred day simple moving average is $1.12. Ekso Bionics Holdings, Inc. has a one year low of $0.72 and a one year high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last posted its earnings results on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The business had revenue of $4.13 million for the quarter, compared to analysts’ expectations of $6.00 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. During the same period last year, the business posted ($0.24) EPS. Equities analysts forecast that Ekso Bionics Holdings, Inc. will post -0.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC grew its position in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 596,050 shares of the company’s stock after buying an additional 454,892 shares during the period. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 at the end of the most recent quarter. 6.42% of the stock is owned by hedge funds and other institutional investors.

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.